Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11243MR)

This product GTTS-WQ11243MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11243MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6962MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ6881MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ10000MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ4561MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ12196MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ13191MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15441MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ10056MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW